PathFast cTnI-II diagnostic test regulatory update

FDA granted 510(k) clearance to PathFast cTnI-II test from Mitsubishi's Mitsubishi Chemical Medience Corp. company as an aid in diagnosing acute myocardial infarction. The chemiluminescent immunoassay...